Breast MRI showdown: which contrast agent is better?

NCT ID NCT03730051

Completed Diagnosis Sponsor: University of Massachusetts, Worcester Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study compared two MRI contrast agents, Dotarem and Gadavist, in 300 women undergoing breast MRI. The goal was to see if Dotarem is as effective as Gadavist at enhancing breast lesions for clearer images. Participants were randomly assigned to receive one of the two agents, and radiologists graded the image quality. The results could help doctors choose the best contrast agent for breast cancer detection.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gadoterate meglumine (Dotarem) and gadobutrol (Gadavist)
What this could lead to: If successful, this could show that Dotarem is as good as Gadavist for breast MRI, giving doctors more options for clear imaging.
What could go wrong: This is a completed Phase 4 study focused on image quality, not on curing or treating disease. The results may not change current practice significantly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BENIGN BREAST DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast disorder breast fibrocystic disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST DISEASES

Contacts and locations

Locations

UMass Medical School

Worcester, Massachusetts, 01655, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.